Made-for-Advertising Sites: What They Are and How They Drain Pharma Budgets
Made-for-advertising sites explained for pharma buyers: what MFA sites are, why they pass standard checks, and how to find and exclude them.
The short answer
Made-for-advertising (MFA) sites exist mainly to resell ad space. They buy cheap traffic, fill pages with ads, auto-refresh, and slideshows, and sell the impressions through programmatic exchanges. They often pass viewability and IVT checks, so they drain pharma budgets quietly. To find them, review spend by domain, look for MFA traits, and move toward PMPs, curated inclusion lists, and vendor MFA filters.
Most pharma teams first meet MFA in a domain report. There is a list of sites with generic names, health or lifestyle content, and a surprising share of spend. Viewability looks great. IVT is low. Nothing in the summary report flagged a problem. That is the pattern.
What made-for-advertising sites are
An MFA site is a business built on arbitrage. It pays for traffic, usually through social, native, or search ads, then earns more from showing programmatic ads to that traffic than it paid to get it. To make the math work, each visit has to produce as many impressions as possible.
Typical traits:
- A high ad-to-content ratio, often with many ad slots above the fold
- Slideshows or "next page" galleries that split one article into 20 page views
- Auto-refreshing ad units
- Most traffic arriving from paid sources rather than search, direct, or social sharing
- Thin, often generic content on broad topics like health tips, finance, and celebrity news
- Short sessions and quick exits
No single trait proves a site is MFA. Plenty of legitimate publishers buy some traffic or run a slideshow. It is the combination that matters.
What the ANA reported about MFA
The ANA's programmatic media supply chain transparency study, released in 2023, looked at a sample of advertiser campaigns. The ANA reported that MFA sites accounted for about 21 percent of impressions in that sample. It also found that campaigns ran across a very large number of domains, many of which received small amounts of spend each.
That number came from a specific sample and period. Your share could be far higher or close to zero, depending on how you buy. Treat it as a reason to check, not as a benchmark.
Why MFA is a particular problem for pharma
Health is a popular MFA topic because health content is cheap to produce and draws broad interest. Contextual segments built around conditions or wellness can pull in MFA pages that use those keywords. Audience-based buys can follow a targeted user onto an MFA page, and the DSP sees a valid, cheap impression on an approved audience.
For HCP campaigns, the risk is different. A physician on your NPI list who lands on a clickbait slideshow is technically reached. But the exposure is unlikely to do much, and it may sit next to content your MLR team would never approve. It also inflates reach and frequency numbers, so the campaign looks healthier than it is. The piece on inventory quality vs. audience quality covers why the right person in the wrong place is still a weak buy.
Why standard quality checks miss MFA
| Check | What MFA usually shows | Why it passes |
|---|---|---|
| Viewability | Often high | Ads are packed into the viewport |
| General IVT | Often normal | Visitors are real people from paid links |
| Brand safety | Usually passes | Content is bland, not harmful |
| ads.txt | Usually authorized | The site sells its own inventory legitimately |
| CPM | Low to moderate | Looks like efficiency |
This is why MFA hides in plain sight. It does not break rules. It just produces low value impressions at scale. The explainer on viewability, attention, and IVT covers why those metrics are floors rather than proof of value.
How to identify MFA in your own buys
- Pull spend by domain and app for the last 90 days. Sort by spend.
- For the top 200 or so, mark each as a known publisher, an endemic health or medical site, or unknown.
- Open the unknowns. Count ads above the fold, check for slideshows and refresh, read a page.
- Ask your verification vendor or DSP whether it offers an MFA classification. Several do. Compare its list against your own review.
- Calculate the share of spend in unknown and likely-MFA domains. That is your starting number.
Look at the long tail too. MFA spend often spreads thinly across hundreds of domains, each too small to notice alone.
How to exclude MFA without losing scale
- Use an MFA filter or blocklist from your DSP or verification partner as a baseline, and review what it catches.
- Move key spend to PMPs and direct deals with known health and news publishers. The trade-offs are covered in direct, PMP, or open auction for pharma.
- Use inclusion lists for HCP campaigns where the set of useful sites is fairly well known.
- Apply quality path rules. Prefer direct paths with short chains. See quality path optimization.
- Watch pacing after the change. Removing MFA often lowers delivery at the same bid. That is expected. Plan for a modest CPM increase rather than reopening the open exchange.
Expect pushback if the campaign is judged on CPM or cost per click. MFA usually lowers both. The broader guide to programmatic media quality explains how to frame quality metrics so a cleaner buy is not penalized for costing more per impression.
Practical takeaway
This week, pull your top 200 domains by spend for one active pharma campaign and mark each one known, endemic, or unknown. Put the share of spend on unknown domains in front of the team. That single number usually starts the MFA conversation better than any industry statistic.
Frequently asked questions
What is a made-for-advertising site?
A made-for-advertising, or MFA, site is built mainly to resell ad space rather than to serve an audience. It buys cheap traffic, often through social or native ads, and packs pages with ad slots, auto-refresh, and slideshows so each visit generates many impressions.
Why do MFA sites pass viewability and IVT checks?
Ads are packed into the screen, so viewability is often high. The visitors are often real people who clicked a paid link, so IVT can look normal. Standard checks were not designed to catch the problem, which is low value rather than fraud.
How much programmatic spend goes to MFA?
The ANA reported in its 2023 programmatic transparency study that MFA made up about 21 percent of impressions in its sample. Results vary widely by advertiser and buying setup, so the only reliable number is the one from your own domain report.
Is MFA the same as ad fraud?
Not exactly. MFA sites usually show real ads to real people, which is why they are hard to block with fraud tools. The issue is that the impressions have little value: short visits, cluttered pages, and people who did not choose the content.
Sources
- ANA, Programmatic Media Supply Chain Transparency Study
- IAB Tech Lab, ads.txt
- Media Rating Council, Standards and Guidelines
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.